Oxytocin Peptide Dosing Chart: mg to IU Conversion, Reconstitution & Half-Life

Oxytocin at a glance

What it is

A nine-amino-acid (nonapeptide) hormone, molecular formula C43H66N12O12S2, molecular weight 1,007.19 Da, produced synthetically for pharmaceutical use to avoid contamination with vasopressin

mg to IU conversion

1 IU is approximately 1.68 mcg, so 1 mg is approximately 595 IU - derived from the WHO 4th International Standard, which assigns 12.5 IU to an ampoule containing approximately 21 mcg

Important unit caveat

The IU is a bioassay potency unit, not a mass unit. Approved products are labelled by activity, and bulk oxytocin is released with a per-lot potency in USP Units per mg - so a research vial labelled only in mg has no assigned potency

Plasma half-life

About 1 to 6 minutes per the FDA-approved label, decreased further in late pregnancy and during lactation

Commonly reported range

Intranasal research most often uses 24 IU per administration; the largest trial used 48 IU daily. Research-vial reports describe roughly 100-200 mcg. No validated non-obstetric dose

Duration by route

Intravenous: uterine response almost immediate, subsiding within 1 hour. Intramuscular: response in 3-5 minutes, persisting 2-3 hours (label)

Approved routes

Intravenous infusion or intramuscular injection. Subcutaneous is not a labelled route for the approved product

Approved indication

Obstetric use only - and the label states it is not indicated for elective induction of labour

Social/behavioural use

Not established. The largest trial - 290 children and adolescents, 48 IU daily intranasally, 24 weeks - found no difference from placebo (NEJM 2021)

Preservative note

The approved injection is preserved with 0.5% chlorobutanol, not benzyl alcohol - a different preservative from the one in bacteriostatic water

Reported ranges from research/community — examples, not recommendations.

What it is / mechanism

Oxytocin is a nonapeptide originally isolated from mammalian pituitary extracts and now prepared synthetically. The FDA-approved labelling gives its empirical formula as C43H66N12O12S2 and its molecular weight as 1,007.19, and notes that the synthetic route is used specifically "to avoid possible contamination with vasopressin (ADH) and other small polypeptides with biologic activity" - vasopressin being structurally close enough to oxytocin that extraction from pituitary tissue could not reliably separate them. The approved mechanism is uterine. Per the label, uterine motility depends on formation of the contractile protein actomyosin under the influence of the calcium-dependent enzyme myosin light-chain kinase; oxytocin promotes contraction by increasing intracellular calcium. It acts through specific receptors in the myometrium, and the label makes a point that matters for any discussion of oxytocin dosing: "the receptor concentration increases greatly during pregnancy, reaching a maximum in early labor at term," so "the response to a given dose of oxytocin is very individualized and depends on the sensitivity of the uterus." The same milligram amount does not produce the same effect in different physiological states, which is a property of the receptor population rather than of the molecule. The label also records that oxytocin "even in its pure form has inherent pressor and antidiuretic properties which may become manifest when large doses are administered" - the structural overlap with vasopressin showing up as pharmacology, not just as a manufacturing problem. The central nervous system effects that drive most non-obstetric interest in oxytocin are a separate question from the myometrial mechanism, and they are separated here deliberately. Peripheral administration and central effect are linked by an assumption - that enough of the peptide reaches the brain to matter - and that assumption has been tested directly. A 2020 study in Nature Communications administered labelled oxytocin intranasally in rhesus macaques and found it did reach the brain (PMID 32494001), which establishes that the delivery route is not simply inert. Whether that translates into a measurable behavioural effect in humans is a different question again, and it has been answered by trial rather than by inference - see the evidence section.

Researched effects

The evidence for oxytocin splits sharply into two bodies, and they are not of the same quality. The obstetric evidence is old, extensive and regulatory-grade. Oxytocin's uterine effects are established well enough that the approved product's label describes onset and duration by route with specificity: after intravenous administration the uterine response "occurs almost immediately and subsides within 1 hour"; after intramuscular injection it "occurs within 3 to 5 minutes and persists for 2 to 3 hours." That is the level of characterisation that comes from decades of clinical use in a monitored setting. The behavioural and social-cognition evidence is where public interest is concentrated, and it is where the strongest single result is a null one. The Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors (SOARS-B, NCT01944046) was published in the New England Journal of Medicine in 2021 (PMID 34644471): a 24-week placebo-controlled trial of intranasal oxytocin in children and adolescents aged 3 to 17 with autism spectrum disorder, 290 participants enrolled, at a total target dose of 48 international units daily. The primary outcome, change from baseline on the Aberrant Behavior Checklist modified Social Withdrawal subscale, was a least-squares mean change of -3.7 in the oxytocin group and -3.5 in the placebo group. The least-squares mean difference was -0.2, with a 95% confidence interval of -1.5 to 1.0 and a P value of 0.61. Secondary outcomes "generally did not differ between the trial groups." That result deserves to be read carefully rather than simply as a negative. Both groups improved by roughly the same amount, which is why a follow-up analysis in 2025 examined predictors of placebo response in the same trial (PMID 39970017). The trial did not find that nothing happened; it found that what happened happened equally without the drug. Adverse-event incidence and severity were also similar between groups, so the trial is evidence about efficacy rather than about harm. The context that makes this the single most relevant study on the page is stated in the paper's own background: experimental studies and small clinical trials had suggested intranasal oxytocin might reduce social impairment, and "oxytocin has been administered in clinical practice to many children with autism spectrum disorder" on the strength of those smaller results. A large, well-powered, appropriately long trial was then run, and the effect did not survive it. That sequence - promising small studies, widespread use, then a null definitive trial - is the most useful thing anyone researching oxytocin can know about the compound, and it is almost never mentioned on vendor pages.

Dosage — reported ranges (overview)

Oxytocin is the compound in this library where the unit question genuinely matters more than the dose question, because two different labelling systems are in circulation and they do not convert cleanly. Approved oxytocin products are labelled by biological activity. The FDA-approved injection is "standardized to contain 10 units of oxytocic hormone/mL," and a second manufacturer's label puts the same thing more explicitly: each mL "possesses an oxytocic activity equivalent to 10 USP Oxytocin Units." Nothing on either label states a mass. Bulk oxytocin drug substance is likewise released on activity - the USP high-potency powder labelling carries a potency field reading "Potency: __________ USP Units / mg," a blank filled in per lot, which means the units-per-milligram figure is an assay result for a specific batch rather than a property of the molecule. Research-grade vials, by contrast, are labelled in milligrams and carry no assigned potency at all. That is the gap the conversion has to bridge, and the bridge is the international standard. The WHO 4th International Standard for Oxytocin (NIBSC 76/575) is the reference preparation against which oxytocin bioassays are calibrated. Its instructions for use state that each ampoule contains approximately 21 micrograms of oxytocin and that the assigned potency is 12.5 international units per ampoule. Dividing one by the other gives the working conversion: 1 IU is approximately 1.68 mcg. 1 mg is approximately 595 IU. A 2 mg vial is therefore approximately 1,190 IU of nominal activity. That conversion is what the searches asking "oxytocin mg to iu" are looking for, and it is correct as far as it goes. The caveat is real and worth stating rather than burying: it is the mass-to-activity ratio of a purified reference preparation with an assigned potency, and applying it to an unassayed research vial assumes that vial contains the same thing at the same purity. The approved products themselves allow meaningful room here - one label permits "up to 16% of total impurities" and another "up to 12.5% decomposition products/impurities" in a released, regulated, assayed product. An unassayed vial has no such bound. On dose itself: the approved product's dosing is obstetric, administered by intravenous infusion or intramuscular injection in a monitored clinical setting, and is not transferable to any other context - the label states the response to a given dose is highly individual and depends on uterine receptor sensitivity, which peaks in early labour at term. For the non-obstetric use most people are researching, the best-documented figure is the one used in the largest trial: 48 international units daily, administered intranasally, in the 24-week SOARS-B trial - which found no difference from placebo. Community protocols for research vials circulate in the range of roughly 100-200 mcg (approximately 60-120 IU) per administration; those are reported conventions with no trial behind them, and this guide does not recommend any of them.

A printable protocol sheet with a reconstitution reference and an injection log comes with All-Access Lifetime.

Reconstitution — bac-water math

The tables below assume a 2 mg vial, the size most commonly encountered in the research-vial market, and a standard U-100 insulin syringe where 100 units equals 1 mL and each unit is 0.01 mL. Concentration is total micrograms divided by millilitres of diluent; volume to draw is the target amount divided by concentration. Because oxytocin is the compound where units are genuinely ambiguous, each row also shows the nominal IU equivalent, converted at 1.68 mcg per IU from the WHO International Standard. Read those IU figures as nominal: they are what the stated milligram amount would correspond to if the vial contained pure oxytocin at the reference preparation's mass-to-activity ratio. The two reference amounts shown are 100 mcg and 200 mcg. They are chosen because they sit inside the range people actually search for and produce legible syringe readings, not because they are recommendations. Every row is drawable in a single U-100 syringe - the largest reading in the table is 30 units.

This is concentration math, not a dose recommendation.

Injection / administration basics

The approved oxytocin injection is labelled for intravenous infusion or intramuscular injection. Subcutaneous administration is not a labelled route for it, which is worth stating plainly because a substantial share of the questions arriving at this page ask about subcutaneous use. That is not a claim that subcutaneous administration is dangerous; it is a statement that the route people are asking about is not the route the regulatory evidence covers, so the label's onset, duration and dosing figures do not transfer to it. The route-specific figures the label does give are unusually concrete, and they follow directly from the very short plasma half-life. Intravenously, the uterine response is almost immediate and subsides within an hour. Intramuscularly, response begins in three to five minutes and persists for two to three hours - the depot effect of an intramuscular injection outlasting the circulating half-life by a wide margin. For the intranasal route that dominates the behavioural literature, the reference point is the SOARS-B protocol: a total target dose of 48 international units daily over 24 weeks. That is the best-documented intranasal regimen in existence for oxytocin, and it is documented because it was the regimen that showed no benefit over placebo. This guide gives no dose, no schedule, no frequency and no route recommendation, and nothing on this page should be read as instructing administration to a person or an animal. The material is compiled for educational reference and research use only.

Half-life & frequency rationale

Oxytocin's plasma half-life is one of the shortest of any compound in this library, and the FDA-approved label states it directly: "Oxytocin has a plasma half-life of about 1 to 6 minutes which is decreased in late pregnancy and during lactation." One to six minutes is the whole circulating story. The label adds that oxytocin is distributed throughout the extracellular fluid, that its "rapid removal from plasma is accomplished largely by the kidney and the liver," and that only small amounts are excreted unchanged in urine. Elimination is enzymatic and fast; there is no depot, no binding-protein reservoir and no meaningful accumulation. The practical consequence is that duration of effect is governed by route and receptor occupancy rather than by persistence in blood. The label's own figures make the point better than any explanation: intravenously, effect subsides within an hour despite a half-life measured in minutes; intramuscularly, effect persists two to three hours, because the injection site releases the peptide slowly enough to outlast its own clearance many times over. A compound with a six-minute half-life producing a three-hour effect is not a contradiction - it is what happens when the rate-limiting step is absorption rather than elimination. The reduction in half-life during late pregnancy and lactation is a genuine physiological effect, attributed to increased circulating oxytocinase activity in those states. It is the reason the label emphasises that response to a given dose is highly individual: both the clearance rate and the receptor population are changing at the same time. For the intranasal route, no equivalent labelled half-life exists, and plasma measurement is a poor proxy in any case, since the question is central concentration rather than circulating concentration. What has been established is that intranasally administered labelled oxytocin does reach the brain in a primate model (Nat Commun 2020, PMID 32494001). What has not been established is a central half-life in humans.

Stacking — overview

Oxytocin is rarely discussed as part of a stack in the way growth-hormone-axis compounds are, because it does not share an axis with them - it acts on its own receptor system with a mechanism, a half-life and a route profile unlike anything else in this library. Where it does appear alongside other compounds, the pairings below are reported conventions rather than studied combinations. No controlled human trial has evaluated oxytocin in combination with any of them, so there is no interaction, additive-effect or safety data for any pairing on this page. One genuine interaction consideration is worth stating because it is mechanistic rather than speculative: oxytocin's antidiuretic property means that anything else affecting fluid balance or sodium handling is operating on the same physiology. That is a reason for caution in principle; it is not a finding from a study, and no such study exists. Our cross-compound Peptide Stacking Guide covers class-collision reasoning and the arithmetic of dosing from separate vials. The per-compound Stacking Module for oxytocin is included with this guide's paid tier.

For how combinations are grouped by research context, the named blends, and why a pre-mixed blend vial cannot be calculated from its total milligrams, see the peptide stacks guide.

Storage & handling

• Lyophilised oxytocin is typically stored refrigerated at 2-8 C and protected from light before reconstitution. The USP bulk drug substance labelling specifies exactly that range - 2 C to 8 C - and adds two conditions worth carrying over: the powder is hygroscopic, so the container should be kept tightly closed, and it should be stored in a dry place protected from light.
• The hygroscopic point is more practical than it sounds. A powder that absorbs atmospheric moisture will pick up water every time a cold vial is opened before it reaches room temperature, which is the ordinary argument for letting a vial equilibrate before entry.
• The approved injection is preserved with 0.5% chlorobutanol - not benzyl alcohol. This is a real difference rather than a technicality: a research vial reconstituted with Bacteriostatic Water for Injection, USP is preserved with 0.9% benzyl alcohol, a different antimicrobial agent from the one in the approved oxytocin product. Both are recognised preservatives for multiple-dose parenteral use; they are not interchangeable substances.
• The approved injection is also formulated at a distinctly low pH - the label gives a target of 3.5, with acetic acid and ammonium acetate as buffers - which reflects the fact that oxytocin's stability in solution is pH-dependent. Bacteriostatic water is near-neutral, so a reconstituted research vial is not in the same chemical environment as the commercial product and should not be assumed to share its shelf life.
• Bacteriostatic water is conventionally treated as good for 28 days after first puncture when refrigerated. Sterile water contains no preservative and does not support repeated entry into a multiple-dose vial. Given that approved oxytocin products carry explicit allowances for decomposition products of up to 12.5-16%, minimising further degradation - refrigerated, dark, unshaken, not left at room temperature - is the part of preservation actually within anyone's control. Our comparison of the two diluents is at the bacteriostatic water vs sterile water guide.

Evidence File

The Oxytocin Evidence File: The Results That Never Left the Registry

Oxytocin is not a compound with thin evidence. It carries one of the deepest human trial records of anything sold as a research peptide, and a large share of that record has never been summarised anywhere a buyer would look, because it sits as numeric tables on ClinicalTrials.gov attached to trials that produced no journal article. This file works outward from the registry rather than from the review literature: which trials posted results and which were published, what doses they actually gave and in which unit system, what the terminated and withdrawn records say in the investigators' own words, and what one pharmacokinetic study shows when the same people receive the compound by two routes.

• 162 oxytocin studies carry posted results on ClinicalTrials.gov
• Registered daily intranasal totals run from 6 IU to 180 IU
• Eight single doses, 8 IU to 84 IU, five or six people at each
• One Phase 1 stopped because plasma oxytocin could not be measured

Sourcing File

The Oxytocin Sourcing File: A Milligram Is Not a Potency

The free reference page already establishes that approved oxytocin is released on activity rather than on mass, so a vial labelled only in milligrams carries no assigned potency. This file is about what sits underneath that sentence and what to do with it: which salt the material actually is and how that is provable from two public records, how much of the weighed powder is peptide once the counter-ion is subtracted, the two mass-spectrometry traps that are specific to this molecule and invisible on a typical certificate, the degradation routes that run through its disulfide bridge and the formulation system that suppresses them, and a certificate read line by line for what each line does not establish.

• Acetate is 94.37% net peptide: 67 IU missing from a 2 mg vial
• The dimer's 2+ ion lands exactly on the monomer's [M+H]+, 1007.44373
• Veterinary oxytocin is 20 USP units/mL, twice the human injection
• A registry compounding formula implies 55 to 61 units per milligram

Benefit & Outcome Review

The Oxytocin Benefit Review: Thick Evidence, Pointing the Wrong Way

Most research peptides are graded against an evidence base too thin to judge. Oxytocin is the opposite case, and it needs a different kind of review. For nearly every claim attached to it there is a placebo-controlled trial with a prespecified primary outcome, sometimes more than one, and the honest task is not to guess but to read what those primaries returned. This review grades each marketed claim against the trial that tested it, in the units the instrument itself uses, keeps human, animal and in-vitro evidence in separate rows, names the exceptions where oxytocin was numerically ahead rather than hiding them, and separates the findings a careless reader could turn into a positive from the ones that would deserve it.

• Six trials, six unrelated conditions, placebo at least as good in all six
• FSFI rose 26% on oxytocin and 31% on placebo in the same crossover
• 67.7% of the treatment effect in female sexual dysfunction is placebo
• Nasal plasma peaks near 10 minutes and is 7.2 pg/mL by 60

Guide FAQ

Quick answers about guide scope, access, and educational use context.